Stay updated with breaking news from Dan Chevallard. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced the initiation...
Viracta Therapeutics to Present at the Jefferies Virtual Healthcare Conference News provided by Share this article SAN DIEGO, May 27, 2021 /PRNewswire/ -- Viracta Therapeutics, Inc. (Viracta or the Company), a precision oncology company targeting virus-associated malignancies, today announced that Company management will present at the Jefferies Virtual Healthcare Conference taking place June 1-4, 2021. The Company will also participate in one-on-one investor meetings at the conference. Details on the presentation can be found below. Date: About Viracta Therapeutics, Inc. Viracta is a prec...
Viracta Therapeutics to Host Key Opinion Leader Webinar Virtual KOL event to focus on the unmet medical need in relapsed/refractory EBV-positive lymphoma and the design of NAVAL-1, a global pivotal trial Event to take place on Thursday, May 20th at 2:00 PM ET News provided by Share this article Share this article SAN DIEGO, May 18, 2021 /PRNewswire/ -- Viracta Therapeutics, Inc. (Nasdaq: VIRX) (Viracta), a precision oncology company targeting virus-associated malignancies, will host a key opinion leader (KOL) webinar on nanatinostat and valganciclovir for the treatment of relapsed/refractor...
/PRNewswire/ -- Viracta Therapeutics, Inc. (Nasdaq: VIRX) (Viracta or the Company), a precision oncology company targeting virus-associated malignancies, today...
Viracta Therapeutics Strengthens Company Leadership with New Appointments to the Board of Directors and Management Team Stephen Rubino, Ph.D., MBA and Barry J. Simon, M.D. appointed to the Board of Directors Cheryl A. Madsen, RAC appointed as Senior Vice President, Regulatory Affairs News provided by Share this article Share this article SAN DIEGO, March 4, 2021 /PRNewswire/ -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that it has strengthened its leadership team with the appointments of Drs. Stephen Rubi...